Obesity's Dark Side: Unveiling the Role of FBLN7 in Adipose Tissue Damage
Fibrosis, a condition caused by excessive extracellular matrix (ECM) buildup, is a significant player in the dysfunction of adipose tissue and obesity-related insulin resistance. Recent research has pointed to adipogenic stem and precursor cells (ASPCs) as key contributors to ECM protein production and the initiation of adipose tissue fibrosis. In this study, we utilized single-cell RNA sequencing to uncover a distinct group of ASPCs intimately linked to ECM function.
Intriguingly, within this subset, we observed a significant increase in the production of Fibulin-7 (FBLN7), a secreted glycoprotein, in obese mice. This trend was mirrored in humans, where FBLN7 levels were elevated in visceral fat of obese individuals and correlated with clinical metabolic traits. But here's where it gets fascinating: when we delved deeper, we found that mice lacking FBLN7 in ASPCs, when exposed to a calorie-rich diet, exhibited reduced adipose tissue fibrosis and inflammation, along with enhanced systemic metabolic health. And this is the part most researchers have been eager to understand: the absence of FBLN7 in ASPCs suppressed TGF-β-induced fibrogenic responses, while its overexpression intensified them.
The underlying mechanism involves FBLN7 interacting with thrombospondin-1 (TSP1) through its EGF-like calcium-binding domain, stabilizing the TSP1 protein. This interaction then promotes the conversion of latent TGF-β to its active form, triggering TGFBR1/Smad signaling pathways. To further explore the therapeutic potential, we engineered an anti-FBLN7 neutralizing antibody, which remarkably mitigated diet-induced adipose tissue fibrosis. These findings strongly imply that FBLN7, originating from ASPCs, plays a pivotal role in adipose tissue fibrosis and could be a promising therapeutic target for obesity-related complications.
Controversial Interpretation: Some experts argue that while FBLN7 inhibition shows promise in preclinical models, its long-term effects on overall health remain uncertain. Could targeting FBLN7 inadvertently impact other physiological processes? What are your thoughts on the potential risks and benefits of this novel therapeutic approach?
